Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center
Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
05/25/2022
Interview with Dr. Zeynep Eroglu, Medical Oncologist, Moffitt Cancer Center
Dr. Zeynep Eroglu is a medical oncologist at Moffitt Cancer Center in Florida. Dr. Eroglu’s research interests are translational and…
|
05/25/2022
FAQ and Update on AIM at Melanoma’s International Melanoma Tissue Bank Consortium
TISSUE IS THE ISSUE AIM at Melanoma’s major research initiative—the International Melanoma Tissue Bank Consortium (IMTBC)—is the first of its…
|
05/25/2022
COVID-19 Has Created a Backlog of Undiagnosed Cancers, Including Melanoma
By Erin Bekes In a study by Dr. Antoine Eskander and colleagues described in the Journal of the National Comprehensive…
|
12/04/2021
FDA Approves KEYTRUDA for Stage IIB and IIC Melanoma Patients
December 4, 2021 (Richmond, California) Yesterday, Merck announced that the U.S. Food and Drug Administration (FDA) has approved Keytruda…
|
|
10/07/2021
Relatlimab/Nivolumab Application for Frontline Advanced Melanoma Validated by EMA
October 1, 2021 Kristi Rosa REPOST from OncLive The European Medicines Agency has validated its marketing authorization application for the…
|
|
09/27/2021
Vaccines 2021—Major Advances in Preventing Death from Infection and Malignancy
By Kim Margolin, M.D., FACP, FASCO Vaccine background and brief history The word “vaccine” comes from the Latin word vacca…
|
|
09/20/2021
Immunotherapy treatment may be appropriate for patients with earlier stages of melanoma
Source: University of Pittsburgh (September 20, 2021) An immunotherapy called pembrolizumab reduced cancer recurrence after surgery in patients with stage…
|
|
09/20/2021
USDA Accepts for Priority Review Bristol Myers Squibb’s Application for LAG-3-Blocking Antibody Relatlimab and Nivolumab Fixed-Dose Combination as Treatment for Patients with Unresectable or Metastatic Melanoma
09/20/2021 The application is based on Phase 2/3 RELATIVITY-047 trial, in which the relatlimab and nivolumab fixed-dose combination demonstrated a…
|
|
09/18/2021
Adjuvant Immunotherapy Prolongs Recurrence-Free Survival in Resected Stage II B/C Melanoma
LUGANO, Switzerland – The first randomised phase III clinical trial in stage II melanoma has shown a 35% reduction in the…
|
|
08/25/2021
Nouscom Begins Phase Ib Trial of Personalized Vaccine, Keytruda Combo in Melanoma, Lung Cancer
August 24, 2021 Expands DecisionDx®-Melanoma Coverage to Veterans Health Administration and Military Health System Medical Centers NEW YORK – Nouscom…
|
|
Recent Posts
Sep. 27, 2022
President’s Letter | September 2022
Sep. 27, 2022
Val Guild Honored at 2022 ASCO Annual Conference
Sep. 27, 2022
AIM Welcomes Ann Garst Taylor as New Director of Community Engagement
Sep. 27, 2022
AIM Welcomes Michelle Bessett as New Director of National Walks & Events
Sep. 16, 2022